


Topoisomerase II inhibitor 20

Cat. No.:	HY-158061
Molecular Formula:	C ₂₂ H ₂₃ F ₂ N ₅ O ₂ S
Molecular Weight:	459.51
Target:	Topoisomerase; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Topoisomerase II inhibitor 20 (Compound 3e) is a potent topoisomerase II (Topoisomerase II) inhibitor with an IC ₅₀ of 0.98 μM. Topoisomerase II inhibitor 20 induces apoptosis and has broad-spectrum anticancer activity ^[1] .								
IC₅₀ & Target	Topoisomerase II 0.98 μM (IC ₅₀)								
In Vitro	<p>Topoisomerase II inhibitor 20 (1.90 μM; 24 h) exhibits cell arrest in the G2-M phase, thereby inhibiting cell proliferation and inducing apoptosis^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Leukemia SR cells</td> </tr> <tr> <td>Concentration:</td> <td>1.90 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>caused a significant increase in the G2-M phase with 49.26% in comparison to control (5.25%).</td> </tr> </table>	Cell Line:	Leukemia SR cells	Concentration:	1.90 μM	Incubation Time:	24 h	Result:	caused a significant increase in the G2-M phase with 49.26% in comparison to control (5.25%).
Cell Line:	Leukemia SR cells								
Concentration:	1.90 μM								
Incubation Time:	24 h								
Result:	caused a significant increase in the G2-M phase with 49.26% in comparison to control (5.25%).								

REFERENCES

[1]. Adly ME, et al. Design, synthesis and in vitro anticancer activity of some new lomefloxacin derivatives. Sci Rep. 2024 Mar 14;14(1):6175

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA